The McGill Genome Centre hosts one of the first gold-level core facilities certified for Olink technology in Canada. Using Proximity Extension Assay (provided by Olink Proteomics), the Biomarker platform can provide quantification of up to 1164 clinically relevant protein biomarkers in plasma and other biological sample of human origin.

A total of 15 different “Olink Target-96” panels are available from Olink Proteomics: six disease area-focus panels, e.g. cardiovascular disease (CVD II and CVD III), oncology (Oncology II and Oncology III), Neurology, Inflammation, Immuno-Oncology and seven additional panels focused on important biological processes such as Cardiometabolic, Metabolism, Cell Regulation, Development, Immune-Response, Neuro-Exploratory and Organ Damage. Each panel of 92 biomarkers is focused on a specific area of disease or key biology processes.

Additionally, Mouse Exploratory is designed for mouse studies and offers 92 assays for murine proteins which are also detectable in human serum and plasma.

Olink Target-96 span a broad dynamic range of protein, covering wide expected ranges of detection. This extremely sensitive antibody and real-time PCR-based technology allows accurate quantification of human plasma proteins present in concentrations below picogram per milliliter, such as interleukines and hormones. As only very little sample-volume of body fluid is necessary, this methodology can be applied for various epidemiologic or clinical research cohorts.